Physician profile
David Milbauer
NPI 1497727432
$10,200.63
in general payments reported to CMS, 2019-2025
32 companies · $13.94 in 2025
The $13.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $1,600 · 2021: $2,236 · 2022: $1,721 · 2023: $1,823 · 2024: $1,226 · 2025: $13.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,110.02 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $995.33 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $718.60 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $628.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $624.13 | 2019-2024 | |
| Esperion Therapeutics, INC. | $611.15 | 2021-2024 | Nexletol |
| Novo Nordisk INC | $558.09 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $535.44 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $509.95 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $487.60 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $459.71 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $453.54 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $435.25 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $380.54 | 2019-2022 | |
| Abbott Laboratories | $293.53 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $206.29 | 2019-2023 | Belsomra |
| Biogen, INC. | $183.91 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $147.48 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $129.29 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $94.01 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $60.61 | 2019-2020 | |
| Eisai INC. | $59.86 | 2020-2021 | |
| Allergan, INC. | $50.23 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.35 | 2022-2024 | Rexulti |
| Arbor Pharmaceuticals, INC. | $35.22 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $29.30 | 2024 | Voquezna |
| Almatica Pharma LLC | $23.53 | 2023 | Gralise, Loreev Xr |
| Medtronic, INC. | $21.14 | 2023 | Interstim |
| Idorsia Pharmaceuticals US INC | $14.40 | 2024 | Quviviq |
| Bardy Diagnostics, INC. | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Milbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.